Form 4 Tracker
Michael Thomas Henderson

Director; Director, Chief Executive Officer · 7 filings · Latest: May 8, 2026

Apogee Therapeutics, Inc.
Spyre Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
APGE
HENDERSON MICHAEL THOMASMay 13, 2026
Proposed Sale
$82.4760,000$4.9M
SYRE
Michael Thomas HendersonDirectorMay 8, 2026
Sale
$74.4080,000$6.0M88,606
SYRE
MICHAEL HENDERSONMay 8, 2026
Proposed Sale
$73.1080,000$5.8M
APGE
Michael Thomas HendersonDirector, Chief Executive OfficerApr 16, 2026
Option Exercise
$22.863,000$68.6K1,135,987
APGE
Michael Thomas HendersonDirector, Chief Executive OfficerApr 8, 2026
Sale
$82.5820,000$1.7M1,132,987
APGE
Michael Thomas HendersonDirector, Chief Executive OfficerMar 11, 2026
Sale
$74.7820,000$1.5M1,152,987
APGE
Michael Thomas HendersonDirector, Chief Executive OfficerFeb 11, 2026
Sale
$63.3520,000$1.3M1,172,987
APGE
HENDERSON MICHAEL THOMASFeb 11, 2026
Proposed Sale
$64.0060,000$3.8M
APGE
Michael Thomas HendersonDirector, Chief Executive OfficerJan 14, 2026
Sale
$81.1120,000$1.6M1,192,987
APGE
HENDERSON MICHAEL THOMASNov 13, 2025
Proposed Sale
$66.98100,000$6.7M
APGE
HENDERSON MICHAEL THOMASMar 5, 2025
Proposed Sale
$30.1510,000$301.5K
APGE
HENDERSON MICHAEL THOMASFeb 5, 2025
Proposed Sale
$40.5815,000$608.7K
APGE
HENDERSON MICHAEL THOMASJan 8, 2025
Proposed Sale
$48.8515,000$732.7K
APGE
HENDERSON MICHAEL THOMASDec 4, 2024
Proposed Sale
$46.5815,000$698.7K
APGE
HENDERSON MICHAEL THOMASNov 6, 2024
Proposed Sale
$59.2315,000$888.4K
APGE
HENDERSON MICHAEL THOMASOct 2, 2024
Proposed Sale
$56.2340,000$2.2M
APGE
HENDERSON MICHAEL THOMASSep 4, 2024
Proposed Sale
$47.6240,000$1.9M